{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:09:39Z","timestamp":1790503779034,"version":"4.1.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010544","name":"Exelixis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010544","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.clcc.2019.02.005","type":"journal-article","created":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T03:00:29Z","timestamp":1551236429000},"page":"81-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma"],"prefix":"10.1016","volume":"18","author":[{"given":"Anwaar","family":"Saeed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Al-Jumayli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raed","family":"Al-Rajabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2019.02.005_bib1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.21037\/tgh.2018.07.02","article-title":"Precision medicine in cholangiocarcinoma","volume":"3","author":"Pellino","year":"2018","journal-title":"Transl Gastroenterol Hepatol"},{"key":"10.1016\/j.clcc.2019.02.005_bib2","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1053\/j.gastro.2013.10.013","article-title":"Pathogenesis, diagnosis, and management of cholangiocarcinoma","volume":"145","author":"Rizvi","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clcc.2019.02.005_bib3","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jhep.2017.03.026","article-title":"Emerging molecular therapeutic targets for cholangiocarcinoma","volume":"67","author":"Rizvi","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.clcc.2019.02.005_bib4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","article-title":"Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"385","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.clcc.2019.02.005_bib5","doi-asserted-by":"crossref","first-page":"e115383","DOI":"10.1371\/journal.pone.0115383","article-title":"Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications","volume":"9","author":"Churi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clcc.2019.02.005_bib6","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clcc.2019.02.005_bib7","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention","volume":"24","author":"Lowery","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2019.02.005_bib8","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.clcc.2019.02.005_bib9","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1634\/theoncologist.2013-0352","article-title":"New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing","volume":"19","author":"Ross","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.clcc.2019.02.005_bib10","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/jcp.21260","article-title":"The role of the EGFR signaling in tumor microenvironment","volume":"214","author":"De Luca","year":"2008","journal-title":"J\u00a0Cell Physiol"},{"key":"10.1016\/j.clcc.2019.02.005_bib11","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2005.05.3579","article-title":"Phase II study of erlotinib in patients with advanced biliary cancer","volume":"24","author":"Philip","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2019.02.005_bib12","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S1470-2045(10)70247-3","article-title":"Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study","volume":"11","author":"Gruenberger","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2019.02.005_bib13","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1470-2045(14)70212-8","article-title":"Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial","volume":"15","author":"Malka","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2019.02.005_bib14","first-page":"42","article-title":"Overexpression of the HER2\/neu gene: a new therapeutic possibility for patients with advanced gallbladder cancer","volume":"7","author":"Roa","year":"2014","journal-title":"Gastrointest Cancer Res"},{"key":"10.1016\/j.clcc.2019.02.005_bib15","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/annonc\/mdm006","article-title":"Gene amplification and protein overexpression of HER-2\/neu in human extrahepatic cholangiocarcinoma as detected by chromogenic in situ hybridization and immunohistochemistry: its prognostic implication in node-positive patients","volume":"18","author":"Kim","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2019.02.005_bib16","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0168-8278(02)00057-0","article-title":"Gene amplification and mRNA and protein overexpression of c-erbB-2 (HER-2\/neu) in human intrahepatic cholangiocarcinoma as detected by fluorescence in situ hybridization, in situ hybridization, and immunohistochemistry","volume":"36","author":"Ukita","year":"2002","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.clcc.2019.02.005_bib17","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13045-015-0155-z","article-title":"HER2\/neu-directed therapy for biliary tract cancer","volume":"8","author":"Javle","year":"2015","journal-title":"J\u00a0Hematol Oncol"},{"issue":"4 Suppl","key":"10.1016\/j.clcc.2019.02.005_bib18","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1200\/jco.2016.34.4_suppl.335","article-title":"A\u00a0phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy","volume":"34","author":"Javle","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2019.02.005_bib19","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1200\/JCO.2014.60.7341","article-title":"Phase I dose-escalation study of JNJ-42756493, an oral pan\u2013fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors","volume":"33","author":"Tabernero","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"15 Suppl","key":"10.1016\/j.clcc.2019.02.005_bib20","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1200\/JCO.2017.35.15_suppl.4017","article-title":"ARQ 087, an oral pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 genetic aberrations","volume":"35","author":"Mazzaferro","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2019.02.005_bib21","doi-asserted-by":"crossref","first-page":"8031","DOI":"10.1074\/jbc.M115.698472","article-title":"A\u00a0hippo and fibroblast growth factor receptor autocrine pathway in cholangiocarcinoma","volume":"291","author":"Rizvi","year":"2016","journal-title":"J\u00a0Biol Chem"},{"issue":"Suppl 8","key":"10.1016\/j.clcc.2019.02.005_bib22","first-page":"viii205","volume":"29","author":"Hollebecque","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2019.02.005_bib23","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1200\/JCO.2010.33.9473","article-title":"Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers","volume":"29","author":"Bekaii-Saab","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2019.02.005_bib24","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"15 Suppl","key":"10.1016\/j.clcc.2019.02.005_bib25","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2017.35.15_suppl.4015","article-title":"Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: results from the cholangiocarcinoma dose escalation and expansion cohorts","volume":"35","author":"Lowery","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2019.02.005_bib26","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1200\/JCO.2010.28.4075","article-title":"Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II consortium study","volume":"28","author":"Lubner","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2019.02.005_bib27","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(09)70333-X","article-title":"Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study","volume":"11","author":"Zhu","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2019.02.005_bib28","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.3748\/wjg.v21.i7.2096","article-title":"FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma","volume":"21","author":"Guion-Dusserre","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clcc.2019.02.005_bib29","doi-asserted-by":"crossref","first-page":"1407-e136","DOI":"10.1634\/theoncologist.2018-0044","article-title":"Ramucirumab plus pembrolizumab in patients with previously treated advanced or metastatic biliary tract cancer: nonrandomized, open-label, phase I trial (JVDF)","volume":"23","author":"Arkenau","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.clcc.2019.02.005_bib30","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/annonc\/mdw371.104","article-title":"Cisplatin and gemcitabine plus ramucirumab or merestinib or placebo in first-line treatment for advanced or metastatic biliary tract cancer: a double-blind, randomized phase 2 trial","volume":"27","author":"Valle","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2019.02.005_bib31","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.bcp.2006.12.031","article-title":"Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma","volume":"73","author":"Huether","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.clcc.2019.02.005_bib32","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1007\/s10637-011-9719-0","article-title":"SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma","volume":"30","author":"El-Khoueiry","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clcc.2019.02.005_bib33","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/sj.bjc.6605458","article-title":"Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial","volume":"102","author":"Bengala","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2019.02.005_bib34","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/bjc.2013.432","article-title":"A\u00a0phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas","volume":"109","author":"Lee","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2019.02.005_bib35","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/cncr.31872","article-title":"A\u00a0phase 2 trial of regorafenib as a single agent in patients with chemotherapy refractory advanced and metastatic biliary adenocarcinoma\/cholangiocarcinoma","volume":"125","author":"Sun","year":"2019","journal-title":"Cancer"},{"issue":"Suppl","key":"10.1016\/j.clcc.2019.02.005_bib36","article-title":"Multi-institutional phase II trial of single agent regorafenib in refractory advanced biliary cancers","volume":"36","author":"Kim","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 4","key":"10.1016\/j.clcc.2019.02.005_bib37","article-title":"A\u00a0multicenter phase Ib-IIR trial assessing activity of regorafenib in combination with modified gemcitabine-oxaliplatin (mGEMOX) in patients with advanced biliary tract cancer (aBTC)","volume":"36","author":"Assenat","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2019.02.005_bib38","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/1078-0432.CCR-06-0833","article-title":"Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer","volume":"12","author":"Bianco","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2019.02.005_bib39","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/sj.bjc.6604988","article-title":"Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma","volume":"100","author":"Yoshikawa","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2019.02.005_bib40","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/annonc\/mdu576","article-title":"A\u00a0randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study","volume":"26","author":"Santoro","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2019.02.005_bib41","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1002\/cncr.30571","article-title":"A\u00a0phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma","volume":"123","author":"Goyal","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.clcc.2019.02.005_bib42","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2019.02.005_bib43","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/jim-2016-000342","article-title":"Immune checkpoint inhibitors in malignancies with mismatch repair deficiency: a review of the state of the current knowledge","volume":"65","author":"Naboush","year":"2017","journal-title":"J\u00a0Investig Med"},{"key":"10.1016\/j.clcc.2019.02.005_bib45","doi-asserted-by":"crossref","first-page":"62","DOI":"10.21037\/cco.2016.10.04","article-title":"Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency","volume":"5","author":"Silva","year":"2016","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.clcc.2019.02.005_bib46","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.clcc.2019.02.005_bib47","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2019.02.005_bib48","first-page":"95","article-title":"Cholangiocarcinoma - evolving concepts and therapeutic strategies","volume":"15","author":"Rizvi","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clcc.2019.02.005_bib49","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1001\/jamaoncol.2016.4574","article-title":"Harnessing the immune system as a therapeutic tool in virus-associated cancers","volume":"3","author":"Santana-Davila","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clcc.2019.02.005_bib50","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev-immunol-020711-075008","article-title":"Cancer and inflammation: an old intuition with rapidly evolving new concepts","volume":"30","author":"Trinchieri","year":"2012","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.clcc.2019.02.005_bib51","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1002\/hep.28635","article-title":"The case for immune-based approaches in biliary tract carcinoma","volume":"64","author":"Duffy","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.clcc.2019.02.005_bib52","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jhep.2012.02.022","article-title":"Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma","volume":"57","author":"Palmer","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.clcc.2019.02.005_bib53","doi-asserted-by":"crossref","first-page":"338","DOI":"10.4251\/wjgo.v7.i11.338","article-title":"Immunotherapeutic approaches in biliary tract carcinoma world","volume":"7","author":"Marks","year":"2015","journal-title":"J\u00a0Gastrointest Oncol"},{"key":"10.1016\/j.clcc.2019.02.005_bib54","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.clcc.2019.02.005_bib55","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1002\/cncr.30254","article-title":"Biliary cancer: utility of next-generation sequencing for clinical management","volume":"122","author":"Javle","year":"2016","journal-title":"Cancer"},{"issue":"Suppl 3","key":"10.1016\/j.clcc.2019.02.005_bib56","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1016\/S0959-8049(16)30326-4","article-title":"Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: interim results of KEYNOTE-028","volume":"51","author":"Bang","year":"2015","journal-title":"Eur J Cancer"},{"issue":"Suppl 5","key":"10.1016\/j.clcc.2019.02.005_bib57","article-title":"A\u00a0Phase II multi institutional study of nivolumab in patients with advanced refractory biliary tract cancers (BTC)","volume":"29","author":"Kim","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2019.02.005_bib58","series-title":"Oral presentation at: Gastrointestinal Cancers Symposium","article-title":"Lenvatinib plus checkpoint inhibitors in patients (pts) with advanced intrahepatic cholangiocarcinoma (ICC): preliminary data and correlation with next-generation sequencing","author":"Lin","year":"2018"},{"key":"10.1016\/j.clcc.2019.02.005_bib59","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/modpathol.3800588","article-title":"Immunohistochemical detection of WT1 protein in a variety of cancer cells","volume":"19","author":"Nakatsuka","year":"2006","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clcc.2019.02.005_bib60","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrc1251","article-title":"Mucins in cancer: protection and control of the cell surface","volume":"4","author":"Hollingsworth","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clcc.2019.02.005_bib61","first-page":"92","article-title":"Phase I trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabinecombination therapy in patients with advanced pancreatic or biliary tract cancer","volume":"34","author":"Kaida","year":"2011","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.clcc.2019.02.005_bib62","first-page":"3575","article-title":"MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer","volume":"25","author":"Yamamoto","year":"2005","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clcc.2019.02.005_bib63","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1158\/1078-0432.CCR-12-3592","article-title":"Long-term vaccination with multiple peptides derived from cancer-testis antigenscan maintain a specific T-cell response and achieve disease stability in advanced biliary tract cancer","volume":"19","author":"Aruga","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2019.02.005_bib64","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1479-5876-12-61","article-title":"Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer","volume":"12","author":"Aruga","year":"2014","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.clcc.2019.02.005_bib65","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3892\/etm.2011.424","article-title":"Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis","volume":"3","author":"Yoshitomi","year":"2012","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.clcc.2019.02.005_bib66","doi-asserted-by":"crossref","first-page":"6555","DOI":"10.4049\/jimmunol.166.11.6555","article-title":"Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection","volume":"166","author":"Soares","year":"2001","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clcc.2019.02.005_bib67","first-page":"955","article-title":"A\u00a0phase I\/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors","volume":"6","author":"Lepisto","year":"2008","journal-title":"Cancer Ther"},{"key":"10.1016\/j.clcc.2019.02.005_bib68","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00595-006-3201-1","article-title":"Intrahepatic cholangiocarcinoma with lymph nodemetastasis successfully treated by immunotherapy with CD3-activated T cells and dendritic cells after surgery: report of a case","volume":"36","author":"Higuchi","year":"2006","journal-title":"Surg Today"},{"key":"10.1016\/j.clcc.2019.02.005_bib69","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1126\/science.1251102","article-title":"Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer","volume":"344","author":"Tran","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.clcc.2019.02.005_bib70","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1631\/jzus.2006.B0719","article-title":"Successful immunological treatment of gallbladder cancer in India\u2014case report","volume":"7","author":"Khan","year":"2006","journal-title":"J\u00a0Zhejiang Univ Sci B"},{"key":"10.1016\/j.clcc.2019.02.005_bib71","first-page":"1759","article-title":"The case of a patient with peritoneal metastasis from cholan giocarcinoma who responded to adoptive immuno-therapy and cetuximab","volume":"40","author":"Kan","year":"2013","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1016\/j.clcc.2019.02.005_bib72","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00534-011-0437-y","article-title":"Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma","volume":"19","author":"Shimizu","year":"2012","journal-title":"J\u00a0Hepatobiliary Pancreat Sci"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002818306030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002818306030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:06:08Z","timestamp":1761519968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002818306030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":71,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S1533002818306030"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2019.02.005","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2019.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}